Key Risk Factors Affect Physicians’ Choice of Treatment in Melanoma
Source: Targeted Oncology, July 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed when they would use monotherapy or doublet therapy in metastatic melanoma.
DISCUSSION QUESTION
- What is your experience with nivolumab plus relatlimab (Opdualag) for metastatic melanoma? What are your perceptions about this regimen?
EVAN J. LIPSON, MD: In the National Comprehensive Cancer Network guidelines, nivolumab [Opdivo] plus ipilimumab [Yervoy], nivolumab plus relatlimab, pembrolizumab [Keytruda], and nivolumab are all category 1.1 Pembrolizumab plus low-dose ipilimumab is a category 2b, although we do occasionally use that in the appropriate patient where you’re concerned about adverse events but they need the ipilimumab coverage. There is a revision in the footnotes talking about this issue of the increased toxicity in patients when you’re adding ipilimumab.